[{"orgOrder":0,"company":"PharmaEssentia","sponsor":"PharmaEssentia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ursodeoxycholic Acid","moa":"Bile acid receptor FXR","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ PharmaEssentia","highestDevelopmentStatusID":"8","companyTruncated":"PharmaEssentia \/ PharmaEssentia"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Pint Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaEssentia \/ PharmaEssentia","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ PharmaEssentia"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Pint Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"PharmaEssentia \/ Pint Pharma","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Pint Pharma"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0.46000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.46000000000000002,"dosageForm":"Injection, Pre-Filled","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"P1101","moa":"Interferon alpha\/beta receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"P1101","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"P1101","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"P1101","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Efficient Pharma Management","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"P1101","moa":"Interferon alpha\/beta receptor","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ Efficient Pharma Management","highestDevelopmentStatusID":"6","companyTruncated":"PharmaEssentia \/ Efficient Pharma Management"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"PharmaEssentia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaEssentia \/ PharmaEssentia","highestDevelopmentStatusID":"1","companyTruncated":"PharmaEssentia \/ PharmaEssentia"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"PharmaEssentia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"Interferon alpha\/beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaEssentia \/ PharmaEssentia","highestDevelopmentStatusID":"7","companyTruncated":"PharmaEssentia \/ PharmaEssentia"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"Interferon alpha\/beta receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"Interferon alpha\/beta receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"Interferon alpha\/beta receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"Interferon alpha\/beta receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"Interferon alpha\/beta receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"Interferon alpha\/beta receptor","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"Interferon alpha\/beta receptor","graph1":"Oncology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"Interferon alpha\/beta receptor","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"Interferon alpha\/beta receptor","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaEssentia \/ PharmaEssentia","highestDevelopmentStatusID":"6","companyTruncated":"PharmaEssentia \/ PharmaEssentia"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"PharmaEssentia","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Src kinase||Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"PharmaEssentia \/ PharmaEssentia","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ PharmaEssentia"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"PharmaEssentia","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Src kinase||Tyrosine-protein kinase SRC","graph1":"Undisclosed","graph2":"Phase I","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"PharmaEssentia \/ PharmaEssentia","highestDevelopmentStatusID":"6","companyTruncated":"PharmaEssentia \/ PharmaEssentia"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Src kinase||Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Phase I","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ Athenex","highestDevelopmentStatusID":"6","companyTruncated":"PharmaEssentia \/ Athenex"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Athenex","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"PharmaEssentia \/ PharmaEssentia","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ PharmaEssentia"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Peg-Methug-Csf","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaEssentia \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"PharmaEssentia \/ Novotech"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Axis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2020","type":"Collaboration","leadProduct":"TCRT-ESO-A2","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ Axis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"PharmaEssentia \/ Axis Therapeutics"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Axis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Cell & Gene Therapy","year":"2020","type":"Collaboration","leadProduct":"TCRT-ESO-A2","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ PharmaEssentia","highestDevelopmentStatusID":"5","companyTruncated":"PharmaEssentia \/ PharmaEssentia"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ PharmaEssentia","highestDevelopmentStatusID":"4","companyTruncated":"PharmaEssentia \/ PharmaEssentia"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ PharmaEssentia","highestDevelopmentStatusID":"4","companyTruncated":"PharmaEssentia \/ PharmaEssentia"}]
Find Clinical Drug Pipeline Developments & Deals by PharmaEssentia
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
